[{"id":"70b78002-ce17-4480-b925-f69956c3deca","acronym":"hSTAR GBM","url":"https://clinicaltrials.gov/study/NCT05052957","created_at":"2021-09-22T11:53:36.877Z","updated_at":"2024-07-02T16:35:17.535Z","phase":"Phase 2","brief_title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","source_id_and_acronym":"NCT05052957 - hSTAR GBM","lead_sponsor":"Leland Metheny","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" IDH2 mutation • IDH wild-type • MGMT expression","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH wild-type • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-28"},{"id":"43117010-8c09-4b16-8b62-84e304e25621","acronym":"","url":"https://clinicaltrials.gov/study/NCT04893356","created_at":"2021-05-19T11:52:40.134Z","updated_at":"2024-07-02T16:35:31.135Z","phase":"","brief_title":"Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)","source_id_and_acronym":"NCT04893356","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dacarbazine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 01/20/2025","study_completion_date":" 01/20/2025","last_update_posted":"2023-10-30"},{"id":"cb9542bd-cd4b-4fdd-b230-bd5afa2d9636","acronym":"ARETHUSA","url":"https://clinicaltrials.gov/study/NCT03519412","created_at":"2021-01-18T17:19:32.520Z","updated_at":"2024-07-02T16:35:35.646Z","phase":"Phase 2","brief_title":"Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status","source_id_and_acronym":"NCT03519412 - ARETHUSA","lead_sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","biomarkers":" TMB • MGMT","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation • MGMT promoter methylation • MGMT expression","tags":["TMB • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation • MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • temozolomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 01/23/2019","start_date":" 01/23/2019","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-09-27"},{"id":"9f076b35-59ec-4151-bae2-fc18060e5d0b","acronym":"CATARTIC","url":"https://clinicaltrials.gov/study/NCT05136326","created_at":"2021-11-29T14:53:37.958Z","updated_at":"2024-07-02T16:35:54.378Z","phase":"Phase 2","brief_title":"Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer","source_id_and_acronym":"NCT05136326 - CATARTIC","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-03-01"},{"id":"da6b2c7b-0baa-4b53-8f8f-39c5005bb54b","acronym":"ERASE-TMZ","url":"https://clinicaltrials.gov/study/NCT05031975","created_at":"2021-09-02T14:52:53.558Z","updated_at":"2024-07-02T16:36:04.553Z","phase":"Phase 2","brief_title":"Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy","source_id_and_acronym":"NCT05031975 - ERASE-TMZ","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" MGMT • CEACAM5","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["MGMT • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/02/2022","start_date":" 05/02/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-09-02"},{"id":"89d39d07-bc8c-450c-86ad-efad94592bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04689347","created_at":"2021-01-19T20:48:19.485Z","updated_at":"2024-07-02T16:36:14.119Z","phase":"Phase 1b","brief_title":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT04689347","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" BRAF • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["BRAF • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • temozolomide • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2022-04-04"},{"id":"a64d5bb3-2405-4cf3-936e-4542c20d4b31","acronym":"MAYA","url":"https://clinicaltrials.gov/study/NCT03832621","created_at":"2021-01-18T18:55:25.728Z","updated_at":"2024-07-02T16:36:14.144Z","phase":"Phase 2","brief_title":"NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03832621 - MAYA","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2022-04-04"},{"id":"032922ec-6a28-4256-89d6-d7eaef7fcd0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01781403","created_at":"2021-01-18T07:51:10.615Z","updated_at":"2024-07-02T16:36:35.015Z","phase":"Phase 1","brief_title":"Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer","source_id_and_acronym":"NCT01781403","lead_sponsor":"Asan Medical Center","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT expression","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 05/10/2013","start_date":" 05/10/2013","primary_txt":" Primary completion: 09/03/2014","primary_completion_date":" 09/03/2014","study_txt":" Completion: 05/04/2016","study_completion_date":" 05/04/2016","last_update_posted":"2021-02-04"},{"id":"92cb7e06-c38e-40eb-ad94-d0480d7e3999","acronym":"ATLANT","url":"https://clinicaltrials.gov/study/NCT02698410","created_at":"2021-01-18T13:10:24.095Z","updated_at":"2024-07-02T16:36:40.479Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.","source_id_and_acronym":"NCT02698410 - ATLANT","lead_sponsor":"Ipsen","biomarkers":" HER-2 • MGMT • SSTR • SSTR2","pipe":" | ","alterations":" MGMT expression","tags":["HER-2 • MGMT • SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 06/18/2019","study_completion_date":" 06/18/2019","last_update_posted":"2020-10-01"},{"id":"5e79e518-b7e4-4b68-a2bf-4b86ff88ab2c","acronym":"SONNET","url":"https://clinicaltrials.gov/study/NCT02231762","created_at":"2021-01-18T10:28:13.866Z","updated_at":"2024-07-02T16:36:59.921Z","phase":"Phase 2","brief_title":"Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET","source_id_and_acronym":"NCT02231762 - SONNET","lead_sponsor":"Ipsen","biomarkers":" SSTR","pipe":" | ","alterations":" MGMT expression • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2019-05-06"},{"id":"1c6bbf66-10e4-4b0e-8e4b-e6e0f3e1d57b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03388372","created_at":"2021-01-18T16:43:24.739Z","updated_at":"2024-07-02T16:37:15.137Z","phase":"Phase 2","brief_title":"Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma","source_id_and_acronym":"NCT03388372","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" EGFR • MGMT","pipe":" | ","alterations":" EGFR expression • EGFR positive • MGMT expression","tags":["EGFR • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • TheraCIM (nimotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 08/18/2010","start_date":" 08/18/2010","primary_txt":" Primary completion: 03/23/2017","primary_completion_date":" 03/23/2017","study_txt":" Completion: 03/23/2017","study_completion_date":" 03/23/2017","last_update_posted":"2018-01-03"},{"id":"7934c116-9e15-4e59-913b-87d180dae4f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00687323","created_at":"2021-01-18T02:34:09.933Z","updated_at":"2024-07-02T16:37:21.310Z","phase":"Phase 2","brief_title":"Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)","source_id_and_acronym":"NCT00687323","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT expression","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 07/30/2007","start_date":" 07/30/2007","primary_txt":" Primary completion: 05/09/2011","primary_completion_date":" 05/09/2011","study_txt":" Completion: 12/23/2012","study_completion_date":" 12/23/2012","last_update_posted":"2017-06-07"},{"id":"68e00b28-bd16-4139-b912-02590df2fe8e","acronym":"PITUICARE-Lyon","url":"https://clinicaltrials.gov/study/NCT02854228","created_at":"2021-01-18T14:00:36.398Z","updated_at":"2024-07-02T16:37:30.070Z","phase":"","brief_title":"PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon","source_id_and_acronym":"NCT02854228 - PITUICARE-Lyon","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" MGMT • SSTR","pipe":" | ","alterations":" MGMT expression • SSTR Expression","tags":["MGMT • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression • SSTR Expression"],"overall_status":"Unknown status","enrollment":" Enrollment 1300","initiation":"Initiation: 02/01/2007","start_date":" 02/01/2007","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2016-08-03"}]